Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04171141




Registration number
NCT04171141
Ethics application status
Date submitted
8/11/2019
Date registered
20/11/2019
Date last updated
7/03/2024

Titles & IDs
Public title
Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.
Scientific title
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07062119 IN PATIENTS WITH ADVANCED GASTROINTESTINAL TUMORS
Secondary ID [1] 0 0
GUCY2C
Secondary ID [2] 0 0
C3861001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Gastrointestinal Tumors 0 0
Colorectal Adenocarcinomas 0 0
Gastric Adenocarcinomas 0 0
Esophageal Adenocarcinomas 0 0
Condition category
Condition code
Cancer 0 0 0 0
Bowel - Back passage (rectum) or large bowel (colon)
Cancer 0 0 0 0
Oesophageal (gullet)
Cancer 0 0 0 0
Other cancer types
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - PF-07062119
Treatment: Drugs - Anti-PD1
Treatment: Drugs - Anti-VEGF

Experimental: Dose Escalation - Single Agent Dose Escalation

Experimental: Dose Finding Anti-PD-1 Combination - Part 1B PF-07062119 plus anti-PD-1

Experimental: Dose Finding anti-VEGF Combination - Part 1B PF-07062119 plus anti-VEGF

Experimental: Dose Expansion Arm A - PF-07062119 as a Single Agent in CRC

Experimental: Dose Expansion Arm B - PF-07062119 in Combination with anti-PD-1 in CRC

Experimental: Dose Expansion Arm C - PF-07062119 in Combination with anti-VEGF in CRC

Experimental: Dose Expansion Arm D - PF-07062119 in Combination with either anti-PD-1 or anti-VEGF in various Tumor Types


Treatment: Drugs: PF-07062119
PF-07062119

Treatment: Drugs: Anti-PD1
Anti-PD1 PF-06801591

Treatment: Drugs: Anti-VEGF
Anti-VEGF IV (bevacizumab)
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of participants with Dose-limiting toxicities (DLT) in Cycle 1
Timepoint [1] 0 0
Baseline up to 28 days (or 42 days as applicable)
Primary outcome [2] 0 0
Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities
Timepoint [2] 0 0
Baseline up to approximately 24 months
Primary outcome [3] 0 0
Duration of Adverse Events (AEs)
Timepoint [3] 0 0
Baseline up to approximately 24 months
Primary outcome [4] 0 0
Number of Participants With Adverse Events (AEs) According to Severity
Timepoint [4] 0 0
Baseline up to approximately 24 months
Primary outcome [5] 0 0
Number of Participants With Adverse Events (AEs) According to Seriousness
Timepoint [5] 0 0
Baseline up to up to approximately 24 months
Primary outcome [6] 0 0
Number of Participants With Adverse Events (AEs) by Relationship
Timepoint [6] 0 0
Baseline up to approximately 24 months
Primary outcome [7] 0 0
Objective Response - Number of Participants With Objective Response for Dose Expansion (Part 2)
Timepoint [7] 0 0
Baseline (1st dosing) up to approximately 24 months
Secondary outcome [1] 0 0
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
Timepoint [1] 0 0
Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months
Secondary outcome [2] 0 0
Incidence of Anti-Drug Antibody (ADA) an Neutralizing Antibodies (Nab) for PF-07062119
Timepoint [2] 0 0
Up to approximately 24 months
Secondary outcome [3] 0 0
Incidence of Anti-Drug Antibody (ADA) an Neutralizing Antibodies anti-PD1
Timepoint [3] 0 0
Up to approximately 24 months
Secondary outcome [4] 0 0
Incidence of Anti-Drug Antibody (ADA) an Neutralizing Antibodies (Nab) for anti-VEGF
Timepoint [4] 0 0
Up to approximately 24 months
Secondary outcome [5] 0 0
Apparent Clearance (CL/F)
Timepoint [5] 0 0
Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months
Secondary outcome [6] 0 0
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]
Timepoint [6] 0 0
Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months
Secondary outcome [7] 0 0
Maximum Observed Plasma Concentration (Cmax)
Timepoint [7] 0 0
Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months
Secondary outcome [8] 0 0
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Timepoint [8] 0 0
Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months
Secondary outcome [9] 0 0
Terminal Half-Life (t1/2)
Timepoint [9] 0 0
Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months
Secondary outcome [10] 0 0
Objective Response - Number of Participants With Objective Response for Dose Escalation
Timepoint [10] 0 0
Baseline up to 24 months
Secondary outcome [11] 0 0
Objective Response - Number of Participants With Objective Response for Dose Finding portion
Timepoint [11] 0 0
Baseline up to 24 months
Secondary outcome [12] 0 0
Minimum Observed Plasma Trough Concentration (Cmin)
Timepoint [12] 0 0
Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months
Secondary outcome [13] 0 0
Progression-Free Survival (PFS) for Dose Expansion
Timepoint [13] 0 0
Baseline to measured progressive disease (up to 24 months)
Secondary outcome [14] 0 0
Duration of Response (DR) for Dose Expansion
Timepoint [14] 0 0
Baseline up to approximately 24 months
Secondary outcome [15] 0 0
Change from baseline of immune cells from tumor biopsies
Timepoint [15] 0 0
Baseline and Cycle 2, Day 1 (each cycle is 28 days)

Eligibility
Key inclusion criteria
- For Part 1 and Part 2, diagnosis of advanced/metastatic colorectal, gastric or
esophageal adenocarcinoma that is resistant to standard therapy or for which no local
regulatory approved standard therapy is available that would confer significant
benefit.

- For Part 2, diagnosis of colorectal adenocarcinoma that is resistant to standard
therapy or for which no standard therapy is available

- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1

- Measurable disease or non-measurable disease and refractory to or intolerant of
existing therapies (Part 1)

- Measurable disease as defined by RECIST 1.1 is required (Part 2)
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases

- Other active malignancy within 3 years prior to randomization, except for adequately
treated basal cell or squamous cell skin cancer, or carcinoma in situ

- Major surgery or radiation within 3 weeks prior to study entry

- Last anti-cancer treatment within 4 weeks prior to study entry

- Active or history of clinically significant autoimmune disease that required systemic
immunosuppressive medication

- Active or history of clinically significant gastrointestinal disease

- Participation in other studies involving investigational drug(s) within 2 weeks prior
to study entry

- Pregnant or breastfeeding female patients

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
19/11/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
28/11/2023
Sample size
Target
Accrual to date
Final
79
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Peter MacCallum Cancer Centre - Melbourne
Recruitment hospital [2] 0 0
The Royal Melbourne Hospital - Parkville
Recruitment postcode(s) [1] 0 0
3000 - Melbourne
Recruitment postcode(s) [2] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Michigan
Country [4] 0 0
United States of America
State/province [4] 0 0
New York
Country [5] 0 0
United States of America
State/province [5] 0 0
Ohio
Country [6] 0 0
United States of America
State/province [6] 0 0
Texas
Country [7] 0 0
Japan
State/province [7] 0 0
Chiba
Country [8] 0 0
Japan
State/province [8] 0 0
Tokyo

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Pfizer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
A phase 1, open-label, dose escalation and expansion study of PF-07062119 in patients with
selected advanced or metastatic gastrointestinal tumors
Trial website
https://clinicaltrials.gov/ct2/show/NCT04171141
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Pfizer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04171141